RayCare in Clinical Use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

The first treatment – for a patient with brain metastasis – was successfully carried out on June 9.

Lausanne University Hosptial (CHUV) has been a RaySearch customer since 2017. In 2021, the relationship with the clinic was extended as CHUV ordered additional RayStation functionality for automated treatment planning and segmentation using artificial intelligence machine learning techniques, as well as support for CyberKnife planning. At the same time the hospital also decided to invest in RayCare and RaySearch’s oncology analytics system RayIntelligence. RayCare is the key component in order for CHUV to coordinate and optimize its workflows and treatment management and will fully replace the hospital’s previous oncology information system.

CHUV and RaySearch are working together in a program that includes various dimensions of treatment optimization, operational efficiency including optimal machine utilization and the new treatment technique FLASH radiotherapy*. Taking RayCare in clinical use with CyberKnife is an important step forward in this program. CHUV will now, in a phased approach, start using RayCare with their other treatment delivery systems. At its completion, CHUV will conduct all major radiation oncology activities, including treatment planning, record and verify, workflow management and data analytics, exclusively with RaySearch software.

Prof Jean Bourhis, Chair of Radiation Oncology Department at Lausanne University Hospital, says: “This is a first successful step towards transitioning our department to a fully automated platform. Our collaboration with RaySearch will bring more safety and security for our treatments.”

Johan Löf, founder and CEO, RaySearch, says: “I am very pleased to hear that the first treatment with CyberKnife using RayStation and RayCare has been successfully carried out at this world-class center. I am impressed by the ambitious program at CHUV and we are happy to support them with a complete software suite that enables optimization of operational efficiency and improved treatment quality.”

Suzanne Winter, President and CEO, Accuray, says: “On behalf of the global Accuray team I congratulate Prof. Bourhis and his colleagues on the treatment of their first patient using the CyberKnife System, RayStation and RayCare. The integration of RayCare with our advanced radiation delivery system will provide additional flexibility and expanded options for treating the high volume of patients the CHUV team sees daily in their practice. We value our long-term partnership with CHUV and look forward to continuing to work with them to optimize patient care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”